Sanofi

Novartis’s Innovative Medicines segment, formerly referred to as its Pharmaceuticals segment, consists of products for therapeutic areas including oncology, respiratory, and established medicines.

The German Stock Index DAX 30 (DAX-INDEX) surged over its 12,000 historical mark in March and was trading at 11,941 on March 9, 2017.

On February 16, 2017, Sanofi was trading at a forward PE multiple of ~13.9x, as compared to the industry average of 15.7x.

Sanofi’s (SNY) established prescription products contributed nearly 28.9% of the company’s total 4Q16 revenues.

Sanofi’s (SNY) 4Q16 revenues were mainly driven by Genzyme and Sanofi Pasteur.

GSK’s Vaccines segment reported a rise of 18.0% to 1.1 billion pounds in 4Q16. The Novartis acquisition has improved sales for the segment.

Revenues for GSK’s Pharmaceuticals segment saw a shift in product performance, falling due to lower sales of its key products Seretide and Advair.

The overall contribution from NVS’s Innovative Medicines segment was ~67%, reaching $8.3 billion in 4Q16.

Sandoz reported a decline of 1% in 3Q16 revenues at constant exchange rates.

The overall contribution of the innovative medicines segment was ~67% at $8,173 million for 3Q16.

In addition to being explored as a monotherapy for AD (atopic dermatitis), Regeneron and Sanofi are also researching Dupixent for other indications.

In Phase 3 trials, SOLO 1 and SOLO 2, Regeneron (REGN) and Sanofi (SNY) tested the efficacy of an investigational therapy, Dupixent, compared to a placebo.

Existing treatment options for AD aren’t tolerated well by the entire patient population. Dupixent might become a preferred regimen in the future.

AbbVie (ABBV) and Neurocrine Biosciences (NBIX) have completed two phase 3 trials to evaluate the efficacy and safety of Elagolix as a treatment option for reducing pain associated with endometriosis as compared to a placebo.

Sandoz, the generics arm of Novartis (NVS), is the number-two generic medicines provider worldwide. It’s number one in differentiated generics.

During the first nine months of 2016, Novo’s (NVO) new generation portfolio garnered 2.8 billion Danish kroner.

Novo’s (NVO) Victoza is a glucagon-like peptide-1 (or GLP-1) therapy for type 2 Diabetes patients.

During 3Q16, Novo’s sales in the US rose 2% in local currency terms to 14.2 billion Danish kroner.

A Bloomberg survey of two brokerage houses on October 24, 2016, reflected a 50% “buy” rating and a 50% “hold” rating for the stock.

Alcon, Novartis’s (NVS) eye care segment, researches, develops, manufactures, and markets eye care products in over 180 countries worldwide.

Novo Nordisk’s search for new molecules through partnerships and other alliances has proven instrumental in strengthening its R&D pipeline.

In addition to its robust drug portfolio, Novo Nordisk boasts a strong research pipeline in the diabetes, hemophilia, obesity, and growth disorder segments.

Insulin sales volumes sold across the world have grown at a compounded average growth rate (or CAGR) of 4.1% from May 2011 to May 2016.

In addition to its robust strategy, Teva Pharmaceutical also boasts of an extensive presence across all levels of the value chain for its generics business.

Sanofi’s diabetes franchise includes Lantus, Toujeo, Amaryl, and Apidra. Lantus, a glargine insulin, contributed 17% of total revenues in fiscal 2015.

LixiLan indicated for type 2 diabetes is a combination of Lantus and lixisenatide. Lantus is Sanofi’s most frequently prescribed diabetes drug.

With improvements in the supply chain and successful launch of new products, GlaxoSmithKline (GSK) is optimistic about its consumer healthcare segment performance.

GlaxoSmithKline (GSK) is focused on strengthening its vaccines business, so it acquired Novartis’s (NVS) meningitis and other vaccines business.

The global pharmaceuticals franchise is GlaxoSmithKline’s (GSK) largest revenue contributor.

Sanofi (SNY) plans to become a leading company in the CHC business. The asset swap will exclude Boehringer Ingelheim’s CHC business in China.

As of June 30, 2016, the animal health business was Sanofi’s operating segment. It will remain an operating segment until the transaction closes.

Sanofi is swapping its animal health business with Boehringer Ingelheim’s consumer healthcare business. The asset swap deal was signed on June 27, 2016.

Sanofi’s Consumer Healthcare segment includes Allegra, Doliprane, Nasacort, and other products. It reported a 4.3% decline in revenues to 800 million euros.

Sanofi’s Diabetes and Cardiovascular revenues declined by ~2% at constant exchange rates to 1.96 billion euros (about $2.21 billion) in 2Q16.

After Sanofi’s reorganization, Genzyme now includes products for multiple sclerosis, rare diseases, and oncology. Genzyme’s sales increased ~19.5% in 2Q16.

As of May 2016, Novo Nordisk (NVO) held a 46% share of the global total insulin market.

Dupilumab has a breakthrough therapy designation from the FDA for the indication of moderate-to-severe atopic dermatitis in adults.

As we’ve discussed, Novartis (NVS) is one of the largest pharmaceutical companies by revenue.

Novartis (NVS) has recorded direct product sales of over $1 billion for each of its ten pharmaceutical products in the last year.

Novo Nordisk’s US sales rose annually by 12% in local currency in 1Q16. North America remained its major market, constituting ~50% of its total revenue.

Some of the challenges the pharmaceutical industry faces include R&D failures, changes in regulatory procedures, litigation, patent expiries, and foreign currency movements.

Based on the last five-year multiple range of ~9x to ~20x, Novartis’s current valuation is neither high nor low.

In 4Q15, Jublia added $68 million to the top line of Valeant—the sixth-largest revenue contributor in 4Q15, down from the second-largest in 3Q15.

Regeneron Pharmaceuticals (REGN) earns revenue from net product sales, collaboration, and technology licenses.

The CHC (consumer healthcare) market forms a part of Sanofi’s (SNY) pharmaceutical segment.

Mylan is a leading pharmaceutical company that operates in more than 140 countries and operates across five different therapeutic areas.

On November 24, Novartis announced that the European Commission had approved Entresto as a therapy for adult patients suffering from symptomatic chronic heart failure with reduced ejection fraction.

Novo Nordisk’s research and development pipeline includes three late-stage insulin studies of faster-acting insulin aspart, semaglutide, and LATIN T1D.

Illumina’s Market Expansion Strategy includes targeting the United States, Europe, and China for population sequencing projects.

Illumina’s key products are based on the company’s NGS (next-generation sequencing) technologies.